← All trials
NCT06206733
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 25, 2024
- Primary completion
- Dec 30, 2026
- Completion date
- Dec 30, 2028
- First posted
- Jan 16, 2024
- Last posted
- Mar 25, 2024
- Enrollment
- 780
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AskGene Pharma, Inc.Lead sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.